Cue Biopharma Inc (CUE)

Overview

Cue Biopharma, Inc. is a trailblazing clinical-stage biopharmaceutical company dedicated to the innovation of a new class of injectable therapeutics. These therapeutics are designed to precisely engage and modulate disease-specific T cells directly within the patient's body, offering a novel approach to treatment. Originally known as Imagen Biopharma, Inc., the company underwent a rebranding to Cue Biopharma, Inc. in October 2016. Founded in 2014, Cue Biopharma has established its headquarters in Boston, Massachusetts, reflecting its commitment to spearheading advancements in the biopharmaceutical sector. Through its ambitious research and development endeavors, Cue Biopharma aims to transform the landscape of therapeutic interventions for various diseases by harnessing the power of the body's own immune system.

Products and Services

The portfolio of Cue Biopharma, Inc. encompasses a range of innovative drug product candidates and programs, each targeting different aspects of diseases through unique mechanisms of action:

• CUE-101: Designed as a lead drug product candidate, CUE-101 specifically targets HPV16+-driven recurrent/metastatic head and neck cancer. This novel therapeutic aims to selectively modulate T cells related to the human papillomavirus (HPV) infection, offering a focused approach to combatting this type of cancer.
• CUE-102: Targets the Wilms' Tumor 1 (WT1) protein, found in various cancers. CUE-102 represents Cue Biopharma's efforts to expand its scope within oncology by addressing tumors that express this commonly found protein, potentially broadening the application of its T cell modulation technology.
• CUE-103: Another promising drug product candidate within the CUE-100 series. Although specific details about CUE-103's target and mechanism of action are not provided, its inclusion in the pipeline underscores the company's ongoing commitment to expanding its repertoire of T cell-modulating therapies.
• Neo-STAT and RDI-STAT Programs: With a focus beyond oncology, these programs entail the development of the CUE-200, CUE-300, and CUE-400 series. Although the specific diseases these programs aim to address are not specified, their inclusion highlights Cue Biopharma's ambition to explore the potential of Immuno-STATs in various therapeutic areas.

In addition to its proprietary technologies and candidates, Cue Biopharma has formed strategic collaborations to enhance and accelerate its development efforts. These include a collaboration with LG Chem, Ltd. focused on immuno-STATs in oncology, a strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. for the advancement of CUE-401 in autoimmune and inflammatory diseases, and a license agreement with Albert Einstein College of Medicine.